Researchers assessed the efficacy of nabilone for improving symptoms of anorexia in patients with NSCLC. In addition, patient appetite, quality of life, and nutritional status were also assessed.
Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.
Loss of appetite and not eating are difficult aspects of cancer for patients’ loved ones to understand. Continued and diligent nurse education can help both patients and families cope with this disturbing effect.
A new drug is proven to offer significantly better outcomes for patients with non-small cell lung cancer who experience this debilitating side effect.
A new drug, anamorelin, has been found to improve appetite and body mass in patients with advanced lung cancer who are experiencing cancer anorexia and cachexia.
